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23, Kay-Tee Khaw24,
Nasser LaoualiID
14, Giovanna MasalaID
25, Peter M. Nilsson15, Kim Overvad12,26,
Anja OlsenID
20, Salvatore Panico27, J. Ramón Quirós28, Olov Rolandsson29,
Miguel Rodrı́guez-BarrancoID
9,30,31, Carlotta SacerdoteID
32, Annemieke M.
W. Spijkerman33, Tammy Y. N. TongID
34, Rosario TuminoID
35, Konstantinos
K. TsilidisID
19,36, John Danesh3,4,37,38, Elio RiboliID
19, Adam S. Butterworth3,4,
Claudia LangenbergID
1, Nita G. ForouhiID
1‡*, Nicholas J. WarehamID1‡*
1 MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom, 2 Westlake Laboratory of
Life Sciences and Biomedicine, Key Laboratory of Growth Regulation and Translational Research of Zhejiang
Province, School of Life Sciences, Westlake University, Hangzhou, China, 3 MRC/BHF Cardiovascular
Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge,
United Kingdom, 4 National Institute for Health Research Blood and Transplant Research Unit in Donor
Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge,
United Kingdom, 5 VITAS, Oslo, Norway, 6 Julius Center for Health Sciences and Primary Care, University
Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, 7 Navarra Public Health Institute,
Pamplona, Spain, 8 Navarra Institute for Health Research (IdiSNA), Pamplona, Spain, 9 CIBER
Epidemiology and Public Health (CIBERESP), Madrid, Spain, 10 Department of Epidemiology, German
Institute of Human Nutrition Potsdam-Rehbruecke, Germany, 11 Public Health Division of Gipuzkoa, San
Sebastian, Spain, 12 Department of Public Health, Aarhus University, Aarhus, Denmark, 13 International
Agency for Research on Cancer, Lyon, France, 14 Center of Research in Epidemiology and Population
Health, UMR 1018 Inserm, Institut Gustave Roussy, Paris South–Paris Saclay University, Villejuif, France,
15 Department of Clinical Sciences, Lund University, Malmö, Sweden, 16 Department of Population Health,
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Abstract
Background
Prior research suggested a differential association of 25-hydroxyvitamin D (25(OH)D) metab-
olites with type 2 diabetes (T2D), with total 25(OH)D and 25(OH)D3 inversely associated with
T2D, but the epimeric form (C3-epi-25(OH)D3) positively associated with T2D. Whether or
not these observational associations are causal remains uncertain. We aimed to examine the
potential causality of these associations using Mendelian randomisation (MR) analysis.
Methods and findings
We performed a meta-analysis of genome-wide association studies for total 25(OH)D (N =
120,618), 25(OH)D3 (N = 40,562), and C3-epi-25(OH)D3 (N = 40,562) in participants of
European descent (European Prospective Investigation into Cancer and Nutrition [EPIC]–
InterAct study, EPIC-Norfolk study, EPIC-CVD study, Ely study, and the SUNLIGHT consor-
tium). We identified genetic variants for MR analysis to investigate the causal association of
the 25(OH)D metabolites with T2D (including 80,983 T2D cases and 842,909 non-cases).
We also estimated the observational association of 25(OH)D metabolites with T2D by per-
forming random effects meta-analysis of results from previous studies and results from the
EPIC-InterAct study. We identified 10 genetic loci associated with total 25(OH)D, 7 loci
associated with 25(OH)D3 and 3 loci associated with C3-epi-25(OH)D3. Based on the meta-
analysis of observational studies, each 1–standard deviation (SD) higher level of 25(OH)D
was associated with a 20% lower risk of T2D (relative risk [RR]: 0.80; 95% CI 0.77, 0.84; p <
0.001), but a genetically predicted 1-SD increase in 25(OH)D was not significantly associ-
ated with T2D (odds ratio [OR]: 0.96; 95% CI 0.89, 1.03; p = 0.23); this result was consistent
across sensitivity analyses. In EPIC-InterAct, 25(OH)D3 (per 1-SD) was associated with a
lower risk of T2D (RR: 0.81; 95% CI 0.77, 0.86; p < 0.001), while C3-epi-25(OH)D3 (above
versus below lower limit of quantification) was positively associated with T2D (RR: 1.12;
95% CI 1.03, 1.22; p = 0.006), but neither 25(OH)D3 (OR: 0.97; 95% CI 0.93, 1.01; p = 0.14)
nor C3-epi-25(OH)D3 (OR: 0.98; 95% CI 0.93, 1.04; p = 0.53) was causally associated with
T2D risk in the MR analysis. Main limitations include the lack of a non-linear MR analysis
and of the generalisability of the current findings from European populations to other popula-
tions of different ethnicities.
Conclusions
Our study found discordant associations of biochemically measured and genetically pre-
dicted differences in blood 25(OH)D with T2D risk. The findings based on MR analysis in a
large sample of European ancestry do not support a causal association of total 25(OH)D or
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25(OH)D metabolites with T2D and argue against the use of vitamin D supplementation for
the prevention of T2D.
Author summary
Why was this study done?
• There is ongoing uncertainty on whether the body’s vitamin D status indicated by blood
25-hydroxyvitamin D (25(OH)D) is relevant to the prevention of type 2 diabetes. There
are conflicting findings from observational studies and a limited number of randomised
controlled trials.
• Prior research did not distinguish between different metabolites of total 25(OH)D,
including 25(OH)D3 and C3-epi-25(OH)D3, an isomer of 25(OH)D3.
• It is not clear whether the associations of 25(OH)D metabolites with type 2 diabetes are
causal, with conflicting findings from prior Mendelian randomisation studies of total 25
(OH)D and no previous Mendelian randomisation studies appraising 25(OH)D
metabolites.
What did the researchers do and find?
• The current research compared observational estimates of the association between 25
(OH)D metabolites and incident type 2 diabetes with Mendelian randomisation esti-
mates based on genetic instruments.
• Using multiple data sources, we performed genome-wide association studies among
120,618 individuals for total 25(OH)D, and among 40,562 individuals for the other vita-
min D metabolites. Among participants of European descent, 10 genetic loci were iden-
tified for total 25(OH)D, 7 loci for 25(OH)D3 and 3 loci for C3-epi-25(OH)D3.
• In meta-analysis of observational studies, we found that each 1–standard deviation
higher level of total 25(OH)D was associated with 20% lower risk of type 2 diabetes. The
result was similar for 25(OH)D3, but for C3-epi-25(OH)D3, a positive association with
type 2 diabetes was found.
• With up to 80,983 type 2 diabetes cases and 842,909 controls, we assessed the association
of genetically predicted differences in total 25(OH)D and its metabolites with type 2 dia-
betes. Neither genetically predicted higher total 25(OH)D level nor genetically predicted
higher levels of 25(OH)D metabolites were significantly associated with type 2 diabetes.
What do these findings mean?
• There were conflicting findings for a link with type 2 diabetes for the observational anal-
ysis of biochemically measured 25(OH)D metabolites versus the genetically predicted
levels of these metabolites.
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• The null findings based on Mendelian randomisation analysis indicate that blood levels
of 25(OH)D or its metabolites are not likely to be causal factors for the development of
type 2 diabetes.
• The current findings together with other evidence from randomised controlled trials do
not support the use of vitamin D supplementation for the prevention of type 2 diabetes.
Introduction
Adequate vitamin D status is crucial for maintaining bone homeostasis, and interest in its
potential beneficial roles in cardiometabolic diseases, including type 2 diabetes (T2D), has
increased recently. Prospective epidemiological studies have consistently reported an inverse
association between circulating 25-hydroxyvitamin D (25(OH)D, a blood marker of vitamin D
status) and T2D risk [1,2], but whether there is a causal relationship between vitamin D status
and T2D remains uncertain. Older randomised controlled trials (RCTs) reported no beneficial
effect of vitamin D supplementation on T2D risk [3,4], but they were limited by issues of sub-
group or post hoc analyses, inadequate dose, or inability to separate the effect of vitamin D
and calcium. The results of the VITAL study for the secondary endpoint of T2D are still
awaited, with the primary endpoints being cancer and cardiovascular disease [5]. With T2D as
a primary endpoint, the D2d RCT recently reported that vitamin D3 supplementation at a dose
of 4,000 IU per day among people at high risk for T2D did not result in a lower risk of T2D
than placebo [6]. This evidence argues against a benefit of vitamin D3 supplementation for the
prevention of T2D, but there are still unresolved issues.
The D2d trial included participants with confirmed prediabetes, so it remains unclear
whether vitamin D supplementation may be more effective at earlier stages in the natural his-
tory of T2D, before beta cell dysfunction. However, designing a trial to examine the effects of
early supplementation poses several challenges including long follow-up, adherence, and cost.
The mean baseline 25(OH)D level was 70 nmol/l in D2d, with the majority of participants vita-
min D replete, and the study was not adequately powered to examine potential effects of sup-
plementation among participants with lower levels of 25(OH)D. Moreover, studies of
supplementation do not directly assess the causal relationship of long-term body vitamin D
status as assessed by blood 25(OH)D metabolite levels, which is relevant biologically given that
blood levels reflect both dietary source and endogenous synthesis. Genetic Mendelian rando-
misation (MR) analysis is a complementary approach to RCTs that, subject to several assump-
tions, can enable the estimation of causal associations using data from observational studies
[7,8]. Given the lack of definitive evidence from RCTs and the challenges of implementing an
ideal RCT, MR studies can be a useful supplementary tool.
Previous MR analyses of 25(OH)D and T2D risk reported conflicting results, with some
MR studies suggesting no association [1,9,10] but others reporting inverse associations
[11,12]. A prior constraint was the use of a genetic instrument that included a limited set of up
to 4 single nucleotide polymorphisms (SNPs) in genes involved in vitamin D synthesis and
metabolism. Specifically, synthesis pathways involve DHCR7 in 25(OH)D synthesis in the skin
and CYP2R1 in hepatic 25-hydroxylation, while metabolism pathways involve GC (or DBP;
encoding vitamin D binding protein) in 25(OH)D transport and CYP24A1 in 25(OH)D catab-
olism [13]. The inclusion of a greater number of genetic variants could generate a more power-
ful genetic instrumental variable for MR analysis. A further limitation to date has been the lack
of a genetic instrument that can distinguish the 25(OH)D metabolites, including 25(OH)D3
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and C3-epi-25(OH)D3, an isomer of 25(OH)D3 [14] that was positively associated with inci-
dent T2D [2]. There is no prior genome-wide association study (GWAS) of 25(OH)D3 to our
knowledge, as past studies were restricted to analysing total 25(OH)D. Similarly, no GWAS to
our knowledge has been performed for C3-epi-25(OH)D3.
Therefore, our objective was to assess the evidence for whether the association between
total 25(OH)D and T2D is causal, using MR based on a genetic instrument derived from an
updated meta-analysis of GWASs for total 25(OH)D. In addition, taking a similar approach,
we also assessed the evidence to support any potentially causal associations with T2D for the
vitamin D metabolites 25(OH)D3 and C3-epi-25(OH)D3 using a novel meta-analysis of
GWASs for 25(OH)D3 and C3-epi-25(OH)D3.
Methods
Study design and populations
We adopted a multi-stage approach comprising 3 parts (defined in a prospective analysis plan;
S1 Text): stage 1, GWASs of total 25(OH)D and vitamin D metabolites (25(OH)D3 and
C3-epi-25(OH)D3); stage 2, MR analysis of T2D risk using GWAS-identified lead genetic vari-
ants; and stage 3, comparison of MR estimates with observational estimates on the association
between vitamin D metabolites and T2D incidence.
At the GWAS stage, for total 25(OH)D, we performed a meta-analysis of GWASs including
120,618 participants of European origin from a number of cohorts as shown in Fig 1: the
Fig 1. Design of the Mendelian randomisation study to estimate the causal association of 25-hydroxyvitamin D metabolites with type 2 diabetes. 25(OH)D,
25-hydroxyvitamin D; GWAS, genome-wide association study.
https://doi.org/10.1371/journal.pmed.1003394.g001
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European Prospective Investigation into Cancer and Nutrition (EPIC)–InterAct study (n =
18,078) [15], EPIC-Norfolk study (n = 10,231) [16], EPIC-CVD study (n = 12,253) [17], Ely
study (n = 690) [18], and publicly available GWAS summary statistics from the SUNLIGHT
consortium (n = 79,366) [19]. We excluded participants duplicated among the EPIC-InterAct
study, EPIC-Norfolk study, and EPIC-CVD study. We then used the UK Biobank dataset (n =
410,826) to replicate the findings from the above GWAS meta-analysis of total 25(OH)D. For
meta-analysis of GWASs of both 25(OH)D3 and C3-epi-25(OH)D3, we included up to 40,562
participants of European origin from the EPIC-InterAct study (n = 18,078), EPIC-Norfolk
study (n = 10,231), and EPIC-CVD study (n = 12,253).
At the MR stage, we estimated the association of GWAS-identified lead genetic variants
with T2D risk, performing a meta-analysis including participants (80,983 T2D cases, and
842,909 non-cases) from the DIAMANTE study (55,005 T2D cases, 400,308 non-cases) [20],
UK Biobank (24,758 T2D cases, 424,575 non-cases) [21], and EPIC-Norfolk study (additional
cases not included in DIAMANTE study: 1,220 T2D cases, 18,026 non-cases) [16].
At stage 3, as a comparison to MR results, we estimated the observational association of
total 25(OH)D, 25(OH)D3, and C3-epi-25(OH)D3 with T2D in the EPIC-InterAct study
(8,331 T2D cases, 11,837 non-cases), adapted from the analysis in our prior publication [2].
For total 25(OH)D, we combined the results from the EPIC-InterAct study with those from a
previous meta-analysis [1].
Ethics statement
Detailed description of each study is provided in S2 Text. All the studies included in the pres-
ent analyses were approved by local ethical committees, and participants provided written
informed consent. Specifically, EPIC-InterAct and EPIC-CVD were approved by local ethics
committees in the participating countries and the institutional review board of the Interna-
tional Agency for Research on Cancer. EPIC-Norfolk was approved by the Norwich local eth-
ics committee, and the Ely study was approved by the Ely local research ethics committee.
Circulating 25(OH)D measurement and genome-wide genotyping
In the EPIC-InterAct study, EPIC-Norfolk study, and EPIC-CVD study, plasma 25(OH)D
metabolites were measured using liquid chromatography–tandem mass spectrometry
(LC-MS/MS) at VITAS (Oslo, Norway; a reference lab in Europe with a Vitamin D External
Quality Assessment Scheme certificate) [2]. In the Ely study, serum total 25(OH)D concentra-
tions were measured by radioimmunoassay. The GWAS summary statistics from the SUN-
LIGHT consortium included data from 31 studies, within which radioimmunoassay, LC-MS/
MS, enzyme-linked immunosorbent assay (ELISA), or chemiluminescence immunoassay was
used for the measurement of the 25(OH)D metabolites [19]. In the UK Biobank, serum total
25(OH)D was measured using chemiluminescence immunoassay. Methods of genome-wide
genotyping in each study are presented in S2 Text.
Statistical analysis
GWASs. For total 25(OH)D, we performed meta-analysis of 9 sets of GWASs (Table 1) includ-
ing 4 in the EPIC-InterAct study (subcohort GWAS array [n = 3,844], subcohort core-exome
array [n = 6,932], non-subcohort GWAS array [n = 3,188], and non-subcohort core-exome
array [n = 4,114]), 1 in the EPIC-Norfolk study (n = 10,231), 2 in the EPIC-CVD study (subco-
hort [n = 887] and non-subcohort [n = 11,366]), 1 in the Ely study (n = 690), and 1 from the
SUNLIGHT consortium (n = 79,366). For 25(OH)D3 and C3-epi-25(OH)D3 (as a binary vari-
able: above versus below the lower limit of quantification [LLQ; 1 nmol/l]), the same datasets
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as total 25(OH)D were used except for the Ely study, where only total 25(OH)D was available.
C3-epi-25(OH)D3 was treated as a binary variable as around half of values were below the LLQ
(i.e., missing) in each individual cohort.
For each participating cohort in the above GWAS discovery, standardised residuals of natu-
ral-log transformed 25(OH)D metabolites were calculated, adjusting for age, sex, BMI, season
of blood collection, and study centre (where appropriate). Then, the GWAS was performed
using linear regression with SNPTEST (v2.5.4) assuming an additive effect, adjusting for the
first 10 genetic principal components of ancestry within each cohort. For the binary C3-epi-25
(OH)D3 variable, the GWAS was performed using logistic regression (above versus below
LLQ) with QUICKTEST (v6.5.2) assuming an additive effect, adjusting for age, sex, BMI, sea-
son of blood collection, study centre (where appropriate), and the first 10 genetic principal
components of ancestry within each cohort.
For each of the 25(OH)D measures (total 25(OH)D, 25(OH)D3, and C3-epi-25(OH)D3),
we performed fixed-effect inverse-variance-weighted (IVW) meta-analysis to combine our
results with published GWAS summary statistics (from the SUNLIGHT consortium, only for
total 25(OH)D) [19] using the software METAL [22]. The quality control thresholds were as
follows: minor allele frequency� 0.01, imputation info score� 0.4, and p-value for Hardy–
Weinberg equilibrium� 1.0 × 10−6. Associated loci were identified using the conventional
threshold for genome-wide statistical significance (p< 5 × 10−8). At each locus, the lead SNP
was identified as the SNP with the lowest p-value within a 1 million base-pair window. To visu-
alise the findings, we generated Manhattan plots and quantile–quantile plots for the genetic
association using R package EasyStrata version 8.5, and regional association plots using Locus-
Zoom software [23]. We used HaploReg v4.1 to explore annotations of the identified lead
SNPs, including the nearest genes, eQTL, GRASP QTL, and previous GWAS hits [24].
We used UK Biobank to replicate our GWAS findings for total 25(OH)D. In the UK Bio-
bank study, standardised residuals of natural-log transformed total 25(OH)D were calculated,
adjusting for age, sex, BMI, season of blood collection, genotype chip, and aliquot number.
GWAS analysis of total 25(OH)D was performed using a linear mixed model with
BOLT-LMM, adjusting for the first 10 genetic principal components of ancestry.
Estimation of genetic correlations and variance explained. Genetic correlation of 25
(OH)D variables with T2D and related glycaemic traits (fasting glucose, insulin, 2-hour glu-
cose, homeostatic model assessment of insulin resistance [HOMA-IR], homeostatic model
assessment of beta cell function [HOMA-B], and glycated haemoglobin [HbA1c]) was esti-
mated with linkage disequilibrium score regression analysis using the meta-analysed GWAS
summary statistics and publicly available datasets in the LD Hub platform [25,26]. Variance in
25(OH)D metabolites explained by the identified lead SNPs was estimated using linear regres-
sion models with individual-level data from the EPIC-Norfolk study and UK Biobank study.
We also calculated the F-statistic in the EPIC-Norfolk study to evaluate the strength of the
genetic instrument.
Observational analysis. For comparison to MR, we estimated the observational associa-
tion between total 25(OH)D and T2D incidence by meta-analysing the results from a previous
meta-analysis [1] together with results from the EPIC-InterAct study we previously published
[2] (cases n = 15,611; non-cases n = 21,106). We also used the published effect estimate of T2D
for 25(OH)D3 in the EPIC-InterAct study [2]. For the observational association between
C3-epi-25(OH)D3 and T2D, we used results based on the EPIC-InterAct study, adapted from
our prior analysis [2], to estimate the relative risk (RR) of T2D comparing those above versus
below the LLQ. To minimise the possibility of residual confounding in the observational asso-
ciation between 25(OH)D and T2D by adiposity, we performed exploratory analyses examin-
ing the influence of additional adiposity-related covariates. Specifically, in the EPIC-InterAct
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study, we included a genetic risk score (GRS) for BMI (generated from 97 BMI-related genetic
variants by summing up the number of risk alleles) [27], and quadratic terms for BMI and
waist-to-hip ratio, to account for a potential non-linear association between adiposity and
T2D.
MR analyses. We performed MR analysis to combine estimates of ‘SNP to 25(OH)D level’
and ‘SNP to T2D’ associations, to estimate the genetically predicted association of the 25(OH)
D variable (either total 25(OH)D or 25(OH)D3) with T2D (odds ratio [OR] per 1-SD increase).
Similarly, we estimated the association of genetically predicted higher C3-epi-25(OH)D3 level
(above versus below the LLQ) with T2D risk. For each of the 25(OH)D variables, we used an
IVW method, MR-Egger method, and weighted median method to pool the estimates from
multiple SNPs [28,29]. We used MR-Egger regression to detect and adjust for potential unbal-
anced pleiotropy in the MR analysis, and we used the weighted median MR method to exam-
ine the robustness of the results and highlight the results if significant heterogeneity of the
associations among different genetic variants was observed. We used the effect estimate from
the 25(OH)D GWAS discovery cohort, not UK Biobank, for the above MR analyses, as there
were a large number of overlapping UK Biobank samples in the T2D GWASs. In response to
peer reviewer comments, we performed analyses using several other MR methods to test the
robustness of our results (S1 Text), including MR-PRESSO [30], MR-RAPS [31], and MRMix
[32], and we further performed a multivariable MR analysis [7] that jointly estimated the
causal association of the highly related traits. In addition, we calculated the statistical power of
the MR analysis, which suggested that our MR had 90% power to detect a 6% difference in
T2D risk per 1-SD change in 25(OH)D (α = 0.05, assuming that the genetic instrument
explains 3.95% of the variance of the exposure).
MR assumptions are violated if there is horizontal pleiotropy, i.e., MR is valid when the
genetic instrument is associated only with the exposure, not other variables that may be poten-
tial confounders. To assess the plausibility of this assumption, we examined the association of
the GWAS-identified lead SNPs with metabolic markers and lifestyle and demographic factors,
using the PhenoScanner tool (v2) [33]. We performed secondary analyses stratifying the
genetic variants into several groups according to their biological roles: for total 25(OH)D and
25(OH)D3, lead SNPs were divided into those in the vitamin D synthesis pathway (CYP2R1
and NADSYN1/DHCR7), in the vitamin D metabolism pathway (GC, CYP24A1), and the oth-
ers (AMDHD1, SEC23A, PADI1, CRCT1, UGT1A5, SULT2A1); for C3-epi-25(OH)D3, lead
SNPs were divided into 2 groups: the SDR9C7 group and the others (which overlapped with 25
(OH)D genes).
We also performed MR analysis to examine the genetically predicted association of the 25
(OH)D metabolites with glycaemic traits, including HOMA-IR, HOMA-B, HbA1c, fasting
insulin, fasting glucose, and 2-hour glucose. R version 3.4.3 and Stata version 14.2 (StataCorp)
were used for the above statistical analyses.
This study is reported as per the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guideline (S1 STROBE Checklist).
Results
Total 25(OH)D and T2D
The average 25(OH)D concentrations (SD) of the cohorts ranged from 38.0 (17.2) nmol/l in
EPIC-InterAct to 58.6 (23.9) nmol/l in the Ely study (Table 1). For total 25(OH)D level (Fig 2;
Table 2), in the meta-analysis of 9 sets of GWASs among 120,618 participants, we identified
10 genetic loci. Of these 10 loci, we confirmed 6 previously discovered loci at GC (rs3755967,
p = 2.48 × 10−465), CYP2R1 (rs116970203, p = 1.19 × 10−64), NADSYN1/DHCR7 (rs12785878,
PLOS MEDICINE 25-hydroxyvitamin D metabolites and type 2 diabetes: A Mendelian randomisation
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p = 5.60 × 10−87), AMDHD1 (rs3213737, p = 2.05 × 10−19), SEC23A (rs8018720, p = 1.46 ×
10−10), and CYP24A1 (rs17216707, p = 1.61 × 10−29). Additionally, we identified 4 novel loci
at PADI1 (rs11203339, p = 4.64 × 10−8), CRCT1 (rs7529325, p = 2.09 × 10−9), UGT1A5
(rs17862870, p = 5.57 × 10−9), and SULT2A1 (rs9304669, p = 4.53 × 10−8) (Table 2; S1–S3
Fig 2. Genome-wide association of circulating 25-hydroxyvitamin D metabolites: Manhattan plot and quantile–quantile plot of all genetic variants from the
meta-analysis. Manhattan plot and quantile–quantile plot for each of total 25-hydroxyvitamin D (A), 25-hydroxyvitamin D3 (B), and C3-epi-25-hydroxyvitamin D3 (C).
Manhattan plot (left): SNPs are plotted on the x-axis according to their positions on each chromosome. The red line indicates the threshold for genome-wide
significance (p< 5 × 10−8). Blue points represent SNPs in the ±100-kb region of a top hit. Loci are annotated with the gene names closest to the SNPs with lowest p-
values (red indicates novel loci identified in the present study). Quantile–quantile plot (right): The x-axis shows the expected −log10 p-values, and the y-axis shows the
observed −log10 p-values. Each SNP is plotted as a red dot, and the black line indicates the null hypothesis of no true association.
https://doi.org/10.1371/journal.pmed.1003394.g002
PLOS MEDICINE 25-hydroxyvitamin D metabolites and type 2 diabetes: A Mendelian randomisation
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003394 October 16, 2020 10 / 21
Figs). The association of total 25(OH)D SNPs with each 25(OH)D metabolite is shown in S1
Table. In the UK Biobank, we replicated associations of all the above 10 SNPs, with p-values <
10−33 (S2 Table).
Total 25(OH)D was not genetically correlated with T2D or glycaemic traits including
HOMA-IR, HOMA-B, HbA1c, fasting insulin, fasting glucose, and 2-hour glucose (S3 Table).
In the EPIC-Norfolk study, the variance explained by the 10 lead SNPs for total 25(OH)D was
3.95% (with F-statistic = 43.1), which was slightly higher than that explained (3.66%) by the 6
previously known loci (GC, CYP2R1, NADSYN1, CYP24A1, AMDHD1, and SEC23A). In the
UK Biobank study, the variance explained by the 10 lead SNPs and the 6 previously known
loci was 3.28% and 3.08%, respectively.
The observational analyses suggested that higher levels of 25(OH)D were associated with
lower risk of T2D (per 1-SD RR: 0.80; 95% CI 0.77, 0.84; p< 0.001) (Fig 3). Further adjustment
for BMI GRS (weighted or unweighted) and quadratic terms for BMI and waist-to-hip ratio
had very little effect on the results (S4 Table).
In the MR analysis (Fig 3), we did not find evidence that genetically predicted higher total
25(OH)D was associated with T2D, with per 1-SD ORs of 0.96 (95% CI 0.89, 1.03; p = 0.23),
1.00 (95% CI 0.91, 1.10; p = 0.99), and 0.98 (95% CI 0.90, 1.06; p = 0.58) for the IVW,
Table 2. Genetic loci identified in the genome-wide analyses for circulating 25(OH)D metabolites.
Circulating vitamin D Gene Role of the gene in
vitamin D
metabolism
Lead SNP Chromosome Position Effect
allele/other
allele
EAF Effect
(beta)
Standard
error
p-Value
Total 25(OH)D
(N = 120,618)
PADI1† Other rs11203339 1 17560972 C/T 0.66 0.012 0.002 4.64 × 10−08
CRCT1† Other rs7529325 1 152492634 A/T 0.08 0.030 0.005 2.09 × 10−09
UGT1A5† Other rs17862870 2 234622742 G/A 0.92 0.021 0.004 5.57 × 10−09
GC Catabolism rs3755967 4 72609398 C/T 0.71 0.106 0.002 2.48 × 10−465
CYP2R1 Synthesis rs116970203 11 14876718 G/A 0.97 0.381 0.022 1.19 × 10−64
NADSYN1/
DHCR7
Synthesis rs12785878 11 71167449 T/G 0.75 0.044 0.002 5.60 × 10−87
AMDHD1 Other rs3213737 12 96379806 G/A 0.43 0.019 0.002 2.05 × 10−19
SEC23A Other rs8018720 14 39556185 G/C 0.17 0.018 0.003 1.46 × 10−10
SULT2A1† Other rs9304669 19 48384385 T/C 0.16 0.052 0.010 4.53 × 10−08
CYP24A1 Catabolism rs17216707 20 52732362 T/C 0.81 0.030 0.003 1.61 × 10−29
25(OH)D3 (N = 40,562) SHQ1† Other rs13084927 3 72709792 C/A 0.83 0.055 0.010 1.94 × 10−08
GC Catabolism rs4588 4 72618323 G/T 0.71 0.266 0.008 6.55 × 10−266
CYP2R1 Synthesis rs116970203 11 14876718 G/A 0.98 0.372 0.023 3.22 × 10−60
NADSYN1/
DHCR7
Synthesis rs28364617 11 71159764 G/T 0.71 0.127 0.008 4.08 × 10−59
AMDHD1 Other rs3819817 12 96378771 C/T 0.45 0.058 0.007 3.59 × 10−16
SULT2A1† Other rs9304669 19 48384385 T/C 0.16 0.054 0.010 1.27 × 10−08
CYP24A1 Catabolism rs17216707 20 52732362 T/C 0.80 0.074 0.009 1.09 × 10−15
C3-epi-25(OH)D3 (as a
binary variable,
N = 40,562)‡
GC Catabolism rs4588 4 72618323 G/T 0.71 0.194 0.016 2.48 × 10−32
NADSYN1/
DHCR7
Synthesis rs28364617 11 71159764 G/T 0.72 0.131 0.017 1.95 × 10−15
SDR9C7† Other rs11172066 12 57319491 T/A 0.14 0.166 0.021 8.08 × 10−15
Beta coefficients are in standard deviation (SD) unit per allele.
†Novel loci identified in the present genome-wide analyses.
‡C3-epi-25(OH)D3 was coded as binary variable: above versus below the lower limit of quantification (1 nmol/l).
25(OH)D, 25-hydroxyvitamin D; EAF, effect allele frequency; SNP, single nucleotide polymorphism.
https://doi.org/10.1371/journal.pmed.1003394.t002
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MR-Egger, and weighted median methods, respectively. Individual 25(OH)D genetic variants
were not significantly associated with metabolic markers or lifestyle or demographic factors
(S4 Fig). Testing the MR-Egger intercept (beta = −0.005; 95% CI −0.011, 0.001; p = 0.15) did
not yield evidence of directional pleiotropy. MR-PRESSO, MR-RAPS, MRMix, and multivari-
able MR produced similar null results (S5 Fig). MR analyses suggested that total 25(OH)D was
not significantly associated with any glycaemic trait (S5 Table).
Fig 3. Association of 25(OH)D metabolites with type 2 diabetes from observational and MR analyses. Estimates (95% CIs) were scaled to represent RRs from
observational analyses or ORs from MR per 1–standard deviation difference in each 25(OH)D metabolite, except for the binary C3-epi-25(OH)D3 variable (above versus
below the lower limit of quantification). For the MR sensitivity analysis for total 25(OH)D, the 4 prior known genes are GC, CYP2R1,NADSYN1/DHCR7, and
CYP24A1; the 25(OH)D synthesis pathway genes are CYP2R1 and NADSYN1/DHCR7; the 25(OH)D metabolism genes are GC and CYP24A1; and the 6 recently
identified genes are PADI1, CRCT1, UGT1A5, AMDHD1, SEC23A, and SULT2A1. For each analysis, 3 MR methods were used, including the IVW method, MR-Egger
method, and weighted median method. For MR analyses based on 2 SNPs, the MR-Egger and weighted median methods could not be applied. For the observational
estimate, the total number of type 2 diabetes cases and non-cases was 15,611 and 21,106, respectively, for total 25(OH)D, and 8,331 and 11,837, respectively, for 25(OH)
D3 (or C3-epi-25(OH)D3). For the MR estimate of all 3 vitamin D variables, the total number of cases and non-cases was 80,983 and 842,909, respectively. 25(OH)D,
25-hydroxyvitamin D; CI, confidence interval; IVW, inverse-variance-weighted; MR, Mendelian randomisation; OR, odds ratio; RR, relative risk; SNP, single nucleotide
polymorphism.
https://doi.org/10.1371/journal.pmed.1003394.g003
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Individual 25(OH)D metabolites and T2D
For 25(OH)D3 (Fig 2; Table 2), we identified 7 novel genetic loci, of which one was a unique
locus at SHQ1 (rs13084927, p = 1.94 × 10−8), while the other 6 were already known to affect
total 25(OH)D: GC (rs4588, p = 6.55 × 10−266), CYP2R1 (rs116970203, p = 3.22 × 10−60), NAD-
SYN1/DHCR7 (rs28364617, p = 4.08 × 10−59), AMDHD1 (rs3819817, p = 3.59 × 10−16),
SULT2A1 (rs9304669, p = 1.27 × 10−8), and CYP24A1 (rs17216707, p = 1.09 × 10−15) (S6–S8
Figs).
For C3-epi-25(OH)D3, we identified 2 loci that overlapped with total 25(OH)D at GC
(rs4588, p = 2.48 × 10−32) and NADSYN1/DHCR7 (rs28364617, p = 1.95 × 10−15), and 1 unique
locus at SDR9C7 (rs11172066, p = 8.08 × 10−15) (Table 2; S9–S11 Figs).
Neither 25(OH)D3 nor C3-epi-25(OH)D3 was genetically correlated with T2D or glycaemic
traits including HOMA-IR, HOMA-B, HbA1c, fasting insulin, fasting glucose, and 2-hour glu-
cose (S4 Table). In the EPIC-Norfolk study, the variance explained by the lead SNPs was 4.58%
for 25(OH)D3 (with F-statistic = 71.2) and 0.41% for C3-epi-25(OH)D3 (binary variable) (with
F-statistic = 15.2).
In the non-genetic observational analyses, circulating 25(OH)D3 was inversely associated
with T2D (per 1-SD RR: 0.81; 95% CI 0.77, 0.86; p< 0.001), and C3-epi-25(OH)D3 was posi-
tively associated with T2D (above versus below LLQ RR: 1.12; 95% CI 1.03, 1.22; p = 0.006)
(Fig 3). Further adjustment for BMI GRS (weighted or unweighted) and quadratic terms for
BMI and waist-to-hip ratio did not change the estimate for 25(OH)D3, while slightly strength-
ening the positive association for C3-epi-25(OH)D3 (S5 Table).
There was no evidence of pleiotropic associations of the genetic variants with metabolic
markers or lifestyle or demographic factors (S12 and S13 Figs). Genetically predicted increases
in 25(OH)D3 or high levels of C3-epi-25(OH)D3 (binary) were not associated with T2D (Fig
3). The findings did not change substantially in the analyses using other MR methods (S5 Fig)
and in secondary analyses stratifying SNPs into different groups (S14 Fig). Testing the MR-Eg-
ger intercept did not yield evidence of directional pleiotropy for 25(OH)D3 (beta = −0.008;
95% CI −0.018, 0.002; p = 0.16) or C3-epi-25(OH)D3 (beta = −0.021; 95% CI −0.073, 0.03; p =
0.65). None of the genetically predicted variations of vitamin D metabolites were significantly
associated with the glycaemic outcomes (S5 Table).
Discussion
Our updated meta-analysis of GWASs for total 25(OH)D levels using data from 120,618 Euro-
pean-descent participants identified 4 novel genetic loci, in addition to 6 loci previously
described [19]. The 4 novel loci were replicated in the UK Biobank study. With GWAS-identi-
fied lead SNPs as a genetic instrument, our MR analysis did not find evidence that total 25
(OH)D was causally associated with T2D. To the best of our knowledge, the present study is
the first GWAS discovery for 25(OH)D3, the major metabolite of circulating total 25(OH)D,
identifying 7 genetic loci, with 1 unique locus and 6 loci overlapping with those for total 25
(OH)D. Similarly, for C3-epi-25(OH)D3, we identified 1 unique locus associated with C3-epi-
25(OH)D3. In the MR analysis, we did not find evidence supporting a causal association
between T2D and 25(OH)D3 or C3-epi-25(OH)D3.
Our current finding of lack of evidence for a causal association of 25(OH)D with T2D in
MR analysis is at variance with the strong inverse observational association between 25(OH)D
and T2D [1,34]. This discrepancy was substantial, with non-overlapping confidence intervals
(RR 0.80 [95% CI 0.77, 0.84] and 0.96 [95% CI 0.89, 1.03], respectively, for the observational
and MR findings), and was not explained by detailed adjustment for the confounding effect of
adiposity in the observational analysis. The reasons for the difference between the
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observational and MR findings remain unclear, but it may be that adjustment for adiposity,
diet, and physical activity using a single imprecise measure of these variables at baseline only
partially reduced the confounding effects of these variables. However, the current lack of evi-
dence for a causal association between 25(OH)D levels and T2D is consistent with recent RCT
evidence (D2d trial) of a lack of benefit from vitamin D supplementation for the prevention of
T2D [6]. The D2d trial was conducted among individuals with prediabetes and thus at high risk
for developing T2D [6]; prior RCTs among postmenopausal women or elderly people also had
null findings [3,4], and the awaited results from the VITAL trial will be further informative.
Several prior MR analyses found inconsistent results [1,9–12]. In a MR analysis among
28,144 T2D cases and 76,344 controls, we previously used 4 prior GWAS-discovered genetic
variants (at GC, CYP2R1, DHCR7, and CYP24A1) as genetic instruments, and found a null
association between 25(OH)D and T2D (OR 1.01 [95% CI 0.75, 1.36] per 1-SD reduction in 25
(OH)D) [1]. When we restricted our analysis to the 2 synthesis-related SNPs (at DHCR7 and
CYP2R1), we still had null findings [1], but this differed from other studies [11,12]. Afzal et al.
examined variants in the 2 synthesis-related genes DHCR7 and CYP2R1 among 96,423 white
Danish adults, reporting that per 20-nmol/l genetically determined reduction in plasma 25
(OH)D there was an allelic effect for DHCR7, with an OR of 1.51 (95% CI 0.98, 2.33), but not
for CYP2R1 (OR 1.02 [95% CI 0.75–1.37]) [11]. The authors acknowledged that their results
were weak and generated a hypothesis for a possible causal inverse association with endoge-
nously synthesised 25(OH)D. Lu et al. detected a significant causal protective effect on T2D
risk using 2 synthesis SNPs related to DHCR7 and CYP2R1 only when including Chinese and
European populations in a meta-analysis [12]. The possibility of uncorrected population strati-
fication by different ethnic groups [35] cannot be excluded, though the authors made attempts
to reduce this possibility by analysing area-specific estimates and combining them using
inverse-variance weighting. Notably, a recent Chinese study did not find a causal association
between 25(OH)D and T2D [10].
Described for the first time, to the best of our knowledge, we found a genome-wide signifi-
cant signal for 25(OH)D3 at SHQ1, which encodes H/ACA ribonucleoprotein assembly factor
and has functions in the processing of ribosomal RNAs, modification of spliceosomal small
nuclear RNAs, and stabilisation of telomerase [36]. In addition, we identified a novel locus at
SDR9C7 for C3-epi-25(OH)D3. SDR9C7 encodes short chain dehydrogenase, whose relation-
ship to the epimerisation of 25(OH)D3 to C3-epi-25(OH)D3 or other metabolites is unknown.
Since the biological role of the epimerase is yet to be discovered [37], the present GWAS results
may provide important insights for future investigation of mechanisms.
Although 25(OH)D3 is usually the major component of total 25(OH)D [2], the causal asso-
ciation of 25(OH)D3, on its own, with T2D risk has not previously been evaluated in MR anal-
ysis. Prior research mainly focused on total 25(OH)D as a biomarker of vitamin D status,
which included a combination of 25(OH)D2 and 25(OH)D3, and, less frequently, C3-epi-25
(OH)D3, the epimeric form of 25(OH)D3, depending on the assay methods. Blood 25(OH)D3
is derived both from diet and from biosynthesis in the skin upon exposure to sunlight, and 25
(OH)D2 is mainly derived from diet, while C3-epi-25(OH)D3 is a metabolite of 25(OH)D3 via
a C3 epimerisation process [37]. Traditional high-performance liquid chromatography, liquid
chromatography–mass spectrometry, ELISA, and chemiluminescent immunoassay methods
do not distinguish C3-epi-25(OH)D3 from 25(OH)D3 and thus include it within the definition
of 25(OH)D3 [38]. Our recent study [2] suggested that blood 25(OH)D3 had an inverse associ-
ation with T2D risk, while C3-epi-25(OH)D3 was positively associated. Therefore, these cur-
rent findings are an important extension to previous research, by including MR analysis for
T2D for total 25(OH)D as well as for 25(OH)D3 and C3-epi-25(OH)D3 separately, as the
results for total 25(OH)D may be potentially confounded by other vitamin D metabolites.
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There are several strengths of this study. To the best of our knowledge, this is the largest
GWAS meta-analysis to date of total 25(OH)D (N = 120,618), and used the most comprehen-
sive genetic instrument for the MR estimate for 25(OH)D and T2D risk (based on 10 SNPs
versus the 4 or 2 used previously [1,11,12]). We replicated our total 25(OH)D GWAS results in
the UK Biobank study, but were unable to evaluate genetic associations for 25(OH)D metabo-
lites since these were not available in UK Biobank. In our MR analysis, we included 80,983
T2D cases, a larger sample than in the largest previous MR study (58,312 T2D cases) [12]. We
performed a novel GWAS on individual vitamin D metabolites—25(OH)D3 and C3-epi-25
(OH)D3—and used results from these in the MR analysis.
A limitation of this study is the lack of generalisability of our results from European popula-
tions to other populations of different ethnicities. Another limitation is that we combined
studies with different study designs to maximise sample size and power for both MR analysis
and observational analysis, even though definitions of endpoints (e.g., contributing to the
degree of misclassification of T2D status) and exposure measurements (e.g., different assays
for 25(OH)D measurement) were not standardised across these studies. In addition, we tested
a linear causal association using the MR approach, but we cannot rule out a potential weak
causal association among people with vitamin D deficiency or insufficiency. Furthermore,
although we did not find convincing evidence for an association of these variants with a variety
of metabolic markers and lifestyle and demographic factors, we cannot rule out the possibility
that horizontal pleiotropy exists for the genetic variants used in the MR analysis. Finally, use of
a binary exposure (C3-epi-25(OH)D3) in MR analysis can potentially lead to violation of the
exclusion restriction assumption: The genetic variant can influence the outcome via the con-
tinuous risk factor even if the binary exposure does not change [39].
The public health implication of the present study, together with prior evidence of null find-
ings from RCTs of vitamin D supplementation, is that focusing on population-wide supple-
mentation to raise blood vitamin D levels is not likely to be an effective strategy for the
prevention of T2D in European populations. However, our current limitations also indicate
there are unresolved issues with important implications for further research. Next steps to
address these issues include, but are not limited to, investigating the reasons for the discrep-
ancy between the observational and MR findings, which likely reflect residual confounding as
discussed above; including populations from different ethnic groups with varying distributions
of 25(OH)D levels; and further increasing sample size and hence statistical power for conduct-
ing MR analysis of non-linear associations. The last of these would help to address whether
there may be effects specifically in those who have hypovitaminosis D or are vitamin D
deficient.
In summary, the present findings using MR do not support a causal association of 25(OH)
D and related metabolites with T2D, despite the strong association seen in observational stud-
ies. The totality of the available evidence from our study and RCTs to date does not justify the
use of vitamin D supplementation for the prevention of T2D.
Supporting information
S1 STROBE Checklist. STROBE checklist.
(DOCX)
S1 Fig. Regional plots of the genome-wide significant loci for total 25-hydroxyvitamin D.
For each of the genetic loci, we used LocusZoom software to draw the regional association
plot.
(TIF)
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S2 Fig. QQ plots by GWAS performed for total 25-hydroxyvitamin D. GWAS, genome-
wide association study; QQ, quantile–quantile.
(TIF)
S3 Fig. Association of novel identified genetic variants with total 25-hydroxyvitamin D in
each GWAS. Effect estimate (95% confidence interval) of each forest plot represents the
change (in standard deviation unit) in total 25-hydroxyvitamin D per allele of the correspond-
ing genetic variant across participating cohorts. GWAS, genome-wide association study.
(TIF)
S4 Fig. Association of total 25-hydroxyvitamin D genetic variants with metabolic markers
and lifestyle and demographic factors. Effect estimate (95% confidence interval) of each for-
est plot represents the change in each trait per allele of the corresponding genetic variant. The
summary statistics shown in the present figure were extracted from the PhenoScanner data-
base (http://www.phenoscanner.medschl.cam.ac.uk/). We extracted the results with the largest
sample size if results from multiple data sources were available in the PhenoScanner database.
The corresponding databases in PhenoScanner were UK Biobank for body mass index and
diastolic and systolic blood pressure, GIANT for waist-to-hip ratio (PMID: 25673412), GLGC
for the 4 lipid traits (PMID: 24097068), MAGIC for the 6 glycaemic traits (PMID: 20081857),
SSGAC for years of educational attainment (PMID: 27225129), and TAG for ever smoker
(PMID: 20418890). p< 0.003 was considered statistically significant after correction for multi-
ple testing within each genetic variant, and none of the results were significant. HbA1c, gly-
cated haemoglobin; HOMA-B, homeostatic model assessment of beta cell function;
HOMA-IR, homeostatic model assessment of insulin resistance.
(TIF)
S5 Fig. Forest plots for the Mendelian randomisation analysis of 25-hydroxyvitamin D
metabolites and type 2 diabetes. The Mendelian randomisation estimate is per 1-SD increase
in vitamin D metabolite, except for the binary C3-epi-25(OH)D3 variable (above versus below
the lower limit of quantification). None of the results show significant heterogeneity (p = 0.661
from Q-test) or directional horizontal pleiotropy (p = 0.153 from test of Egger intercept). For
multivariable MR analysis, the result of total 25(OH)D or 25(OH)D3 was adjusted for the
genetic variants of C3-epi-25(OH)D3, while the multivariable MR result of C3-epi-25(OH)D3
was adjusted for total 25(OH)D, as the definition of total 25(OH)D includes only 25(OH)D3
and 25(OH)D2, not C3-epi-25(OH)D3. For C3-epi-25(OH)D3, MR-PRESSO result was not
available due to limited number of genetic variants.
(TIF)
S6 Fig. Regional plots of the genome-wide significant loci for 25-hydroxyvitamin D3. For
each of the genetic loci, we used LocusZoom software to draw the regional association plot.
(TIF)
S7 Fig. QQ plots by GWAS performed for total 25-hydroxyvitamin D3. GWAS, genome-
wide association study; QQ, quantile–quantile.
(TIF)
S8 Fig. Association of novel identified genetic variants with 25-hydroxyvitamin D3 in each
GWAS. Effect estimate (95% confidence interval) of each forest plot represents the change (in
standard deviation unit) in total 25-hydroxyvitamin D3 per allele of the corresponding genetic
variant across participating cohorts. GWAS, genome-wide association study.
(TIF)
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S9 Fig. Regional plots of the genome-wide significant loci for C3-epi-25-hydroxyvitamin
D3. For each of the genetic loci, we used LocusZoom software to draw the regional association
plot.
(TIF)
S10 Fig. QQ plots by GWAS performed for C3-epi-25-hydroxyvitamin D3. GWAS,
genome-wide association study; QQ, quantile–quantile.
(TIF)
S11 Fig. Association of novel identified genetic variants with C3-epi-25-hydroxyvitamin
D3 in each GWAS. Effect estimate (95% confidence interval) of each forest plot represents the
change (log odds) in C3-epi-25-hydroxyvitamin D3 per allele of the corresponding genetic var-
iant across participating cohorts. GWAS, genome-wide association study.
(TIF)
S12 Fig. Association of 25-hydroxyvitamin D3 genetic variants with metabolic markers
and lifestyle and demographic factors. The summary statistics shown in the present figure
were extracted from the PhenoScanner database (http://www.phenoscanner.medschl.cam.ac.
uk/). We extracted the results with the largest sample size if results from multiple data sources
were available in the PhenoScanner database. The corresponding databases in PhenoScanner
were UK Biobank for body mass index and diastolic and systolic blood pressure, GIANT for
waist-to-hip ratio (PMID: 25673412), GLGC for the 4 lipid traits (PMID: 24097068), MAGIC
for the 6 glycaemic traits (PMID: 20081857), SSGAC for years of educational attainment
(PMID: 27225129), and TAG for ever smoker (PMID: 20418890). p< 0.003 was considered
statistically significant after correction for multiple testing within each genetic variant, and
none of the results were significant. HbA1c, glycated haemoglobin; HOMA-B, homeostatic
model assessment of beta cell function; HOMA-IR, homeostatic model assessment of insulin
resistance.
(TIF)
S13 Fig. Association of C3-epi-25-hydroxyvitamin D3 genetic variants with metabolic
markers and lifestyle and demographic factors. Effect estimate (95% confidence interval) of
each forest plot represents the change in each trait per allele of the corresponding genetic vari-
ant. The summary statistics shown in the present figure were extracted from the PhenoScanner
database (http://www.phenoscanner.medschl.cam.ac.uk/). We extracted the results with the
largest sample size if results from multiple data sources were available in the PhenoScanner
database. The corresponding databases in PhenoScanner were UK Biobank for body mass
index and diastolic and systolic blood pressure, GIANT for waist-to-hip ratio (PMID:
25673412), GLGC for the 4 lipid traits (PMID: 24097068), MAGIC for the 6 glycaemic traits
(PMID: 20081857), SSGAC for years of educational attainment (PMID: 27225129), and TAG
for ever smoker (PMID: 20418890). p< 0.003 was considered statistically significant after cor-
rection for multiple testing within each genetic variant, and none of the results were signifi-
cant. HbA1c, glycated haemoglobin; HOMA-B, homeostatic model assessment of beta cell
function; HOMA-IR, homeostatic model assessment of insulin resistance.
(TIF)
S14 Fig. Mendelian randomisation analysis of 25-hydroxyvitamin D metabolites and type
2 diabetes with stratification of single nucleotide polymorphisms. Mendelian randomisa-
tion (MR) estimate represents the association between a genetically predicted 1–standard devi-
ation increase in 25-hydroxyvitamin D metabolites (except for the binary C3-epi-25(OH)D3
variable: above versus below the lower limit of quantification) and T2D risk. For 25(OH)D3, 4
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prior known genes are GC (rs4588), CYP2R1 (rs116970203), NADSYN1/DHCR7 (rs28364617),
and CYP24A1 (rs17216707). Two genes in the 25(OH)D synthesis pathway are CYP2R1
(rs116970203) and NADSYN1/DHCR7 (rs28364617). Two genes related to 25(OH)D metabo-
lism are GC (rs4588) and CYP24A1 (rs17216707). Three genes, SHQ1, AMDHD1, and
SULT2A1, were recently identified in the present GWAS meta-analysis or by another recent
study. For C3-epi-25(OH)D3, we did sensitivity analysis stratified by the SDR9C7 variant and
the other variants (related to total 25(OH)D), as SDR9C7 is a unique locus associated with
C3-epi-25(OH)D3. The SDR9C7 SNP was rs11172066. 25(OH)D, 25-hydroxyvitamin D; SNP,
single nucleotide polymorphism.
(TIF)
S1 Table. Association of GWAS-identified genetic variants with each of the 25-hydroxyvi-
tamin D metabolites.
(DOCX)
S2 Table. Replication of the GWAS-identified variants for total 25-hydroxyvitamin D in
the UK Biobank study.
(DOCX)
S3 Table. Genetic correlation of 25-hydroxyvitamin D metabolites with type 2 diabetes
and glycaemic traits.
(DOCX)
S4 Table. Observational estimates of the association of 25-hydroxyvitamin D metabolites
with incident type 2 diabetes in the EPIC-InterAct study.
(DOCX)
S5 Table. Mendelian randomisation analysis of 25-hydroxyvitamin D metabolites and gly-
caemic traits.
(DOCX)
S1 Text. Study protocol.
(DOCX)
S2 Text. Description of the participating studies in the present genome-wide association
study for vitamin D metabolites.
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